$1.72
2.00% today
Nasdaq, Feb 05, 03:45 pm CET
ISIN
KYG108301006
Symbol
BYSI
Sector
Industry

BeyondSpring Inc. Stock price

$1.75
+0.09 5.42% 1M
-0.02 1.13% 6M
+0.12 7.36% YTD
+0.69 65.09% 1Y
-1.32 43.00% 3Y
-15.95 90.11% 5Y
-15.05 89.58% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.06 3.48%
ISIN
KYG108301006
Symbol
BYSI
Sector
Industry

Key metrics

Market capitalization $70.53m
Enterprise Value $63.77m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 33.92
P/S ratio (TTM) P/S ratio 37.52
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $1.88m
EBIT (operating result TTM) EBIT $-17.05m
EPS (TTM) EPS $-0.40
Short interest 8.33%
Show more

Is BeyondSpring Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

BeyondSpring Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast BeyondSpring Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast BeyondSpring Inc.:

Buy
100%

Financial data from BeyondSpring Inc.

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
1.88 1.88
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.36 9.36
-
498%
- Research and Development Expense 9.57 9.57
-
509%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -17 -17
74% 74%
-907%
Net Profit -16 -16
-
-828%

In millions USD.

Don't miss a Thing! We will send you all news about BeyondSpring Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BeyondSpring Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
KING OF PRUSSIA, Pa., Jan. 28, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. (“SEED”), a biotechnology company pioneering the discovery of molecular glues for targeted protein degradation (TPD) using its proprietary RITE3™ platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease and Orphan Drug designations to SEED's ST-01156 molecular glue...
Neutral
GlobeNewsWire
8 days ago
FLORHAM PARK, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has entered into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED Therapeutics Inc. (“SEED”), a biotechnology company focused o...
Neutral
GlobeNewsWire
3 months ago
In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of 11.5 months achieved a DCR of 89.3% and Median PFS of 8.6 months In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of 11.5 months achieved a DCR of 89.3% and Median PFS of 8.6 months
More BeyondSpring Inc. News

Company Profile

BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.

Head office Cayman Islands
CEO Lan Huang
Employees 35
Founded 2010
Website www.beyondspringpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today